Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Neil H. Segal"'
Publikováno v:
Clinical Colorectal Cancer. 15:222-227
Background Imprime PGG (β(1,6)-[poly-(1,3)-D-glucopyranosyl]-poly-β(1,3)-D-glucopyranose) is an innate immune cell modulator that primes neutrophils and monocytes/macrophages to exert antitumor activity against complement opsonized tumor cells. In
Autor:
Ashok Kumar Gupta, John A. Blake-Haskins, Rachel E. Sanborn, Peter H. O'Donnell, Zev A. Wainberg, Gerardo Colon-Otero, Alexandra Drakaki, Sunil Sharma, Jason J. Luke, Michael S. Gordon, Marlon Rebelatto, Winston Tan, Neil H. Segal, Xiaoping Jin, John Kurland, Omid Hamid, Saeed Rafii, Christophe Massard, Tyler J. Curiel
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 34, iss 26
Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in patients with advanced urothelial bladder cancer (UB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93711a4f081705da5797621b349d9a99
https://europepmc.org/articles/PMC5569690/
https://europepmc.org/articles/PMC5569690/
Autor:
Vaios Karanikas, F. Sandoval, Victor Moreno, D. Sabanes Bove, Herbert Hurwitz, Luis Paz-Ares, Jose Saro, M.E. Rodriguez, James M. Cleary, Willeke Ros, Neil H. Segal, S. Bouseida, P. Eder, Joan Albanell, Emiliano Calvo, J. Tabernero, Candice Jamois, P. Umana, Mario Perro, Marina Bacac, Christian Klein, Sasha Sreckovic, Aurélien Marabelle, A. Silva, Ignacio Melero, Guillem Argiles
Publikováno v:
Web of Science
Autor:
Willeke Ros, Jose M. Saro Suarez, Emiliano Calvo, Vaios Karanikas, F. Sandoval, Neil H. Segal, James M. Cleary, Maria E. Rodriguez-Ruiz, Herbert Hurwitz, Daniel Sabanes, Victor Moreno, Joan Albanell, Luis Paz-Ares, Sasha Sreckovic, Joseph Paul Eder, Aurélien Marabelle, Ignacio Melero, Guillem Argiles, Josep Tabernero, S. Bouseida
Publikováno v:
Journal of Clinical Oncology. 35:3002-3002
3002 Background: CEA CD3 TCB (RG7802, RO6958688) is a novel T-cell bispecific antibody targeting CEA on tumor cells and CD3 on T cells. In preclinical models, CEA CD3 TCB displays potent anti-tumor activity, leads to increased intra-tumoral T cell in
Autor:
Jedd D. Wolchok, Geoffrey T. Gibney, Rachel E. Sanborn, Shivani Srivastava, Suzanne L. Topalian, Rom Leidner, Naiyer A. Rizvi, C. Passey, Thomas F. Gajewski, J. R. Infante, Sarah Cooley, Praveen Aanur, Erin M. Bertino, William H. Sharfman, W J Urba, F.S. Hodi, Dan McDonald, D. P. Lawrence, X. Gu, Neil H. Segal
Publikováno v:
Annals of Oncology. 27:vi372
Autor:
Patrick Schöffski, S-H.I. Ou, Ashok Kumar Gupta, Joyce M Antal, Keith Steele, Ani Sarkis Balmanoukian, Neil H. Segal, Jared Weiss, Samir N. Khleif, Erminia Massarelli, Xiaoping Jin, Dan P. Zandberg, S.J. Antonia, Julie R. Brahmer, Christophe Massard, Marlon Rebelatto, Anna Spreafico, Colleen Anne Maher
Publikováno v:
Annals of Oncology. 27:vi328
Autor:
Jonathan W. Goldman, Sai-Hong Ignatius Ou, Zev A. Wainberg, Neda Stjepanovic, Ashok Kumar Gupta, Neil H. Segal, Scott J. Antonia, John A. Blake-Haskins, Heather A. Wakelee, John Kurland, Angela Fasolo, Marlon Rebelatto, Sang-We Kim, Alexander I. Spira, Myung-Ju Ahn, Patrick A. Ott, Wenliang Yao, Dirk Jäger
Publikováno v:
Journal of Clinical Oncology. 34:9029-9029
9029Background: The PD-1/PD-L1 axis is an important immune inhibitory pathway contributing to tumor cell escape from immunosurveillance. A Phase 1/2 dose escalation and dose expansion study is ongo...
Autor:
Zev A. Wainberg, John Kurland, Neil H. Segal, Ashok Kumar Gupta, Xiaoping Jin, Omid Hamid, Sunil Sharma, Saeed Rafii, Rachel E. Sanborn, Gerardo Colon-Otero, John A. Blake-Haskins, Michael S. Gordon, Tyler J. Curiel, Alexandra Drakaki, Jason J. Luke, Peter H. O'Donnell, Christophe Massard, Marlon Rebelatto
Publikováno v:
Journal of Clinical Oncology. 34:4502-4502
4502Background: A Phase 1/2 dose escalation and dose expansion study is evaluating the safety and efficacy of durvalumab, a modified human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80, in so...
Autor:
Marlon Rebelatto, Neil H. Segal, Patrick Schöffski, Sai-Hong Ignatius Ou, Matthew G. Fury, Samir N. Khleif, Christophe Massard, Dan P. Zandberg, Ani Sarkis Balmanoukian, Scott J. Antonia, Julie R. Brahmer, Jared Weiss, Xia Li, Keith Steele, Paul B. Robbins, John A. Blake-Haskins, Marcus O. Butler, Erminia Massarelli
Publikováno v:
Journal of Clinical Oncology. 33:3011-3011
3011 Background: Outcomes are poor for patients (pts) with recurrent/metastatic (R/M) SCCHN, and new treatments are needed. An ongoing phase I/II, multicenter, open-label study (NCT01693562) is eva...
Autor:
Naiyer A. Rizvi, Keith Steele, Scott J. Antonia, Jared Weiss, Patrick Schöffski, Wen-Jen Hwu, Martin Gutierrez, John A. Blake-Haskins, Omid Hamid, John Nemunaitis, Michele Maio, Xia Li, Julie R. Brahmer, Marlon Rebelatto, Ani Sarkis Balmanoukian, Sai-Hong Ignatius Ou, Jose Lutzky, Dirk Jaeger, Samir N. Khleif, Neil H. Segal
Publikováno v:
Journal of Clinical Oncology. 33:8032-8032
8032 Background: MEDI4736 (M) is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity. PD-L1 is expressed in NSCLC tumors and may be associated with respon...